000			02014 a2200517 4500
005			20250517033923.0
264		0	_c20150929
008			201509s 0 0 eng d
022			_a1980-5322
024	7		_a10.6061/clinics/2015(04)06 _2doi
040			_aNLM _beng _cNLM
100	1		_aLiu, Mengguo
245	0	0	_aTanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway. _h[electronic resource]
260			_bClinics (Sao Paulo, Brazil) _cApr 2015
300			_a250-6 p. _bdigital
500			_aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAbietanes _xpharmacology
650	0	4	_aAdult
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xpharmacology
650	0	4	_aBlotting, Far-Western
650	0	4	_aCell Migration Assays
650	0	4	_aCell Movement _xdrug effects
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCells, Cultured _xdrug effects
650	0	4	_aCollagen Type I _xanalysis
650	0	4	_aCollagen Type III _xanalysis
650	0	4	_aEnzyme Activation _xdrug effects
650	0	4	_aExtracellular Signal-Regulated MAP Kinases _xdrug effects
650	0	4	_aFemale
650	0	4	_aFluorescent Antibody Technique
650	0	4	_aHumans
650	0	4	_aInterleukin-17 _xanalysis
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMuscle, Smooth, Vascular _xdrug effects
650	0	4	_aMyocytes, Smooth Muscle _xdrug effects
650	0	4	_aReproducibility of Results
650	0	4	_aSalvia miltiorrhiza _xchemistry
650	0	4	_aScleroderma, Systemic _xdrug therapy
650	0	4	_aStatistics, Nonparametric
650	0	4	_aTime Factors
700	1		_aYang, Ji
700	1		_aLi, Ming
773	0		_tClinics (Sao Paulo, Brazil) _gvol. 70 _gno. 4 _gp. 250-6
856	4	0	_uhttps://doi.org/10.6061/clinics/2015(04)06 _zAvailable from publisher's website
999			_c24940330 _d24940330